{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:36:03Z","timestamp":1793756163387,"version":"4.6.1"},"reference-count":56,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T00:00:00Z","timestamp":1484006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish National Science Centre","award":["2014\/15\/B\/NZ7\/00964"],"award-info":[{"award-number":["2014\/15\/B\/NZ7\/00964"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>As cancer development involves pathological vessel formation, 16 angiogenesis markers were evaluated as potential ovarian cancer (OC) biomarkers. Blood samples collected from 172 patients were divided based on histopathological result: OC (n = 38), borderline ovarian tumours (n = 6), non-malignant ovarian tumours (n = 62), healthy controls (n = 50) and 16 patients were excluded. Sixteen angiogenesis markers were measured using BioPlex Pro Human Cancer Biomarker Panel 1 immunoassay. Additionally, concentrations of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) were measured in patients with adnexal masses using electrochemiluminescence immunoassay. In the comparison between OC vs. non-OC, osteopontin achieved the highest area under the curve (AUC) of 0.79 (sensitivity 69%, specificity 78%). Multimarker models based on four to six markers (basic fibroblast growth factor\u2014FGF-basic, follistatin, hepatocyte growth factor\u2014HGF, osteopontin, platelet-derived growth factor AB\/BB\u2014PDGF-AB\/BB, leptin) demonstrated higher discriminatory ability (AUC 0.80\u20130.81) than a single marker (AUC 0.79). When comparing OC with benign ovarian tumours, six markers had statistically different expression (osteopontin, leptin, follistatin, PDGF-AB\/BB, HGF, FGF-basic). Osteopontin was the best single angiogenesis marker (AUC 0.825, sensitivity 72%, specificity 82%). A three-marker panel consisting of osteopontin, CA125 and HE4 better discriminated the groups (AUC 0.958) than HE4 or CA125 alone (AUC 0.941 and 0.932, respectively). Osteopontin should be further investigated as a potential biomarker in OC screening and differential diagnosis of ovarian tumours. Adding osteopontin to a panel of already used biomarkers (CA125 and HE4) significantly improves differential diagnosis between malignant and benign ovarian tumours.<\/jats:p>","DOI":"10.3390\/ijms18010123","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T10:16:18Z","timestamp":1484043378000},"page":"123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5390-9213","authenticated-orcid":false,"given":"Agnieszka","family":"Horala","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Department, Poznan University of Medical Sciences, Polna 33, 60-535 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Swiatly","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-1504","authenticated-orcid":false,"given":"Jan","family":"Matysiak","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Banach","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, Poznan University of Medical Sciences, Polna 33, 60-535 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Nowak-Markwitz","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, Poznan University of Medical Sciences, Polna 33, 60-535 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenon","family":"Kokot","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,1,10]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., and Parkin, D. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Available online: https:\/\/www.iarc.fr\/en\/media-centre\/iarcnews\/2010\/globocan2008.php."},{"key":"ref_2","first-page":"161","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_3","first-page":"937","article-title":"Diagnosis and Management of Ovarian Cancer","volume":"93","author":"Doubeni","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1447-0756.2008.00869.x","article-title":"Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index","volume":"35","author":"Enakpene","year":"2009","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/895019","article-title":"Tumour Angiogenesis: A Growth Area\u2014From John Hunter to Judah Folkman and Beyond","volume":"2013","author":"Stephenson","year":"2013","journal-title":"J. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rahbari, N.N., Schmidt, T., Falk, C.S., Hinz, U., Herber, M., Bork, U., B\u00fcchler, M.W., Weitz, J., Koch, M., and Jemal, A. (2011). Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-286"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1757-2215-6-45","article-title":"The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors","volume":"6","author":"Lawicki","year":"2013","journal-title":"J. Ovarian Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.cca.2012.06.017","article-title":"Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer","volume":"413","author":"Li","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_10","first-page":"13","article-title":"Biomarkers of Angiogenesis in Colorectal Cancer","volume":"7","author":"Mousa","year":"2015","journal-title":"Biomark. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s12253-011-9387-6","article-title":"Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables","volume":"17","author":"Rykala","year":"2011","journal-title":"Pathol. Oncol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2005.09.005","article-title":"Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood","volume":"51","author":"Bremnes","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_13","unstructured":"Avastin (Bevacizumab) Official Patient & Caregiver Website. Available online: http:\/\/www.avastin.com\/patient."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr2903","article-title":"Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3","volume":"13","author":"Kodera","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1073\/pnas.0502178102","article-title":"Serum protein markers for early detection of ovarian cancer","volume":"102","author":"Mor","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/br.2016.682","article-title":"The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer","volume":"5","author":"Wei","year":"2016","journal-title":"Biomed. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.clinbiochem.2013.08.019","article-title":"The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay","volume":"46","author":"Yang","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.drup.2011.02.004","article-title":"Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review","volume":"14","author":"Murphy","year":"2011","journal-title":"Drug Resist. Update"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2007.11.029","article-title":"Gynecologic Oncology Group Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study","volume":"108","author":"Secord","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3816\/COC.2008.n.005","article-title":"HER2 Overexpression\/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study","volume":"1","author":"Guastalla","year":"2008","journal-title":"Clin. Ovarian Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ygyno.2013.12.018","article-title":"A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study","volume":"132","author":"Martin","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","article-title":"An overview of small-molecule inhibitors of VEGFR signaling","volume":"6","author":"Ivy","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-5-46","article-title":"The stem cell factor\/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells","volume":"5","author":"Yasuda","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1038\/onc.2009.189","article-title":"Osteopontin induces angiogenesis through activation of PI3K\/AKT and ERK1\/2 in endothelial cells","volume":"28","author":"Dai","year":"2009","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3892\/or.2010.1106","article-title":"Categorical meta-analysis of Osteopontin as a clinical cancer marker","volume":"25","author":"Weber","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/1541-7786.MCR-10-0463","article-title":"Osteopontin-c splicing isoform contributes to ovarian cancer progression","volume":"9","author":"Tilli","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11373-006-9143-1","article-title":"Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers","volume":"14","author":"Bao","year":"2007","journal-title":"J. Biomed. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11799","DOI":"10.1007\/s13277-014-2314-1","article-title":"Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hu, Z.-D., Wei, T.-T., Yang, M., Ma, N., Tang, Q.-Q., Qin, B.-D., Fu, H.-T., and Zhong, R.-Q. (2015). Diagnostic value of osteopontin in ovarian cancer: A meta-analysis and systematic review. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126444"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10689-015-9847-3","article-title":"Diagnostic values of osteopontin combined with CA125 for ovarian cancer: A meta-analysis","volume":"15","author":"Lan","year":"2016","journal-title":"Fam. Cancer"},{"key":"ref_32","first-page":"3720","article-title":"Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma","volume":"82","author":"Welt","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1093\/humrep\/dep195","article-title":"High serum follistatin levels in women with ovarian endometriosis","volume":"24","author":"Florio","year":"2009","journal-title":"Hum. Reprod."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/147323001204000306","article-title":"High serum levels of follistatin in patients with ovarian cancer","volume":"40","author":"Ren","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2004.08.034","article-title":"PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis","volume":"6","author":"Cao","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drup.2009.12.001","article-title":"Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy","volume":"13","author":"Abdollahi","year":"2010","journal-title":"Drug Resist. Update"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.onc.1209232","article-title":"Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer","volume":"25","author":"Matei","year":"2006","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2010.11.035","article-title":"Overview of anti-angiogenic agents in development for ovarian cancer","volume":"121","author":"Burger","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_39","first-page":"3817","article-title":"Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors","volume":"32","author":"Madsen","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1757-2215-5-23","article-title":"Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab","volume":"5","author":"Madsen","year":"2012","journal-title":"J. Ovarian Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/156800909789057006","article-title":"The role of fibroblast growth factors in tumor growth","volume":"9","author":"Korc","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/ijc.21521","article-title":"From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer","volume":"118","author":"Ouellet","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2010.12.355","article-title":"Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis","volume":"121","author":"Aune","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4161\/cbt.9.2.10280","article-title":"Hepatocyte growth factor enhances ovarian cancer cell invasion through down-regulation of thrombospondin-1","volume":"9","author":"Wei","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2015.08.010","article-title":"Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum","volume":"139","author":"Nakamura","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_46","first-page":"318","article-title":"Evaluation of leptin serum concentrations during surgery and first-line chemotherapy in primary epithelial ovarian cancer patients","volume":"18","author":"Grabowski","year":"2014","journal-title":"Contemp. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21100","DOI":"10.18632\/oncotarget.4228","article-title":"Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: An explanation for poor outcomes in obese women","volume":"6","author":"Kato","year":"2015","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.1997.537","article-title":"Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels","volume":"76","author":"Yamamoto","year":"1997","journal-title":"Br. J. Cancer"},{"key":"ref_49","first-page":"754","article-title":"Markers and modulators of angiogenesis in ovarian cancer","volume":"1","author":"Bednarek","year":"2007","journal-title":"Ginekol. Pol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ijc.24028","article-title":"Functional significance of VEGFR-2 on ovarian cancer cells","volume":"124","author":"Spannuth","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/03007995.2015.1131152","article-title":"Angiogenesis inhibitors for patients with ovarian cancer: A meta-analysis of 12 randomized controlled trials","volume":"32","author":"Li","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejogrb.2015.09.008","article-title":"Clinical value of human epididymis protein 4 and the risk of ovarian malignancy algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages","volume":"194","author":"Kotowicz","year":"2015","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1097\/IGC.0000000000000476","article-title":"The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary","volume":"25","author":"Fotopoulou","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_54","unstructured":"Ochiai, K., Shinozaki, H., and Takada, A. (1998, January 16\u201319). A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, USA."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/humupd\/dms047","article-title":"Fertility and borderline ovarian tumor: A systematic review of conservative management, risk of recurrence and alternative options","volume":"19","author":"Darai","year":"2013","journal-title":"Hum. Reprod. Update"},{"key":"ref_56","first-page":"57","article-title":"Performance of PLS regression coefficients in selecting variables for each response of a multivariate PLS for omics-type data","volume":"2","author":"Palermo","year":"2009","journal-title":"Adv. Appl. Bioinform. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/1\/123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:25:51Z","timestamp":1760207151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/1\/123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,10]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1]]}},"alternative-id":["ijms18010123"],"URL":"https:\/\/doi.org\/10.3390\/ijms18010123","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,10]]}}}